|
|
|
Tenax Therapeutics Inc. 
|
2.1 0.16 (0.08%) |
03-05 16:00 |
Open: |
1.94 |
Pre close: |
1.94 |
Target:
|
3.02
|
High: |
2.12 |
Low: |
1.9 |
Resistance:
|
2.59
3.04
|
Volume: |
233,161 |
Market Cap: |
30M |
Support:
|
1.85
1.54
|
|
|
|
Technical Analysis |
Moving Averages |
MA(5):
|
2.13
 |
MACD |
MACD(12,26):
|
-0.04  |
MA(20): |
2.43  |
Signal(12,26,9): |
0.04  |
MA(100): |
1.62  |
Stochastic Oscillator |
%K(14,3):
|
15.20  |
MA(250): |
1.30  |
%D(3): |
16.11  |
Average Volume(K) |
3-Month: |
549471
|
52-Week |
High:
|
3.68 |
10-Days: |
25931 |
Low: |
0.25 |
RSI |
RSI(14):
|
44.17  |
Change(%): |
102.1 |
Financials, Statistics and Valuation |
EPS |
-1.105 |
Return on Equity (ttm) |
-140.8 |
Shares Out. (M) |
14.51 |
EPS Est. Current Year |
-0.360 |
Return on Assets (ttm) |
-73.4 |
Shares Float (M) |
10.25 |
EPS Est. Next Year |
-0.280 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.33 |
EPS Est. Next Quarter |
-0.080 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
32.15 |
Forward EPS |
-9.040 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
576 |
Book Value (p.s.) |
0.590 |
EBITDA (p.s.) |
-0.678 |
P/E |
-1.90 |
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
3.56 |
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-9.01 |
P/S |
0.00 |
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-5.24 |
P/CF |
-3.38 |
|
|
|
|
|